nVerses Capital’s Cytek Biosciences CTKB Stock Holding History

nVerses Capital’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,319	Closed	-$167K	–	347
2026 Q1	$167K	Buy	+38,319	New	+$181K	0.15%	292

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

nVerses Capital's CTKB Position: Q2 2026 in Review

nVerses Capital sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 38,319 shares — an estimated $167K sold.

nVerses Capital first reported a position in CTKB in Q1 2026 and held it in 1 quarter. The position peaked at $167K in Q1 2026. 103 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

nVerses Capital reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 38,319 Cytek Biosciences shares in Q2 2026, an estimated $167K.
nVerses Capital first reported a position in Cytek Biosciences in Q1 2026 and held it in 1 quarter.
nVerses Capital's Cytek Biosciences position peaked at $167K in Q1 2026.
103 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.